The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Browse trials for

• Blepharitis 70

Blepharitis

70 studies on the registry are indexed under Blepharitis; 5 are open to participants now.

This study's enrollment of 313 is above the median of 60 across 62 interventional studies indexed under Blepharitis.

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.

Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.

Study arms

• Experimental
  1

  Drug: Azithromycin ophthalmic solution, 1%

• Placebo comparator
  2

  Drug: Placebo

Interventions

• DrugAzithromycin ophthalmic solution, 1%

  One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days

• DrugPlacebo

  One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days

Primary outcomes

1. Eyelid margin erythema

   Time frame: Two weeks

Secondary outcomes

1. Signs and symptoms of Blepharitis

   Time frame: One week, two weeks, three weeks, four weeks